A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf(Tacrolimus)/ Myfortic and Advagraf (Extended Release Tacrolimus) / Myfortic in de Novo Liver Transplant Recipients.

Trial Profile

A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf(Tacrolimus)/ Myfortic and Advagraf (Extended Release Tacrolimus) / Myfortic in de Novo Liver Transplant Recipients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2011

At a glance

  • Drugs Mycophenolic acid; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 05 Oct 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
    • 05 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Aug 2010 Preliminary results in 20 patients presented at the 23rd International Congress of the Transplantation Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top